Literature DB >> 11192959

Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment.

T Bratel1, A Wennlund, K Carlström.   

Abstract

The aim of the study was to investigate the effects of chronic hypoxaemia on neuroendocrine function in hypoxaemic chronic obstructive pulmonary disease (COPD). The stress level was assessed by measurement of daytime plasma catecholamine and nocturnal urinary catecholamine levels and endocrine function was assessed by measuring serum gonadotropins, peripheral sex hormones and peripheral thyroid hormones, and by measuring thyroid stimulating hormone (TSH), prolactin and growth hormone before and after thyroid releasing hormone challenge in 12 male, stable, hypoxaemic COPD patients before and after at least 4 months of long-term oxygen treatment (LTOT). Mean pre-treatment PaO2 was 7.39 +/- 0.78 kPa and mean nocturnal arterial oxygen saturation (MSaO2) was 86.6 +/- 3.2%. Plasma norepinephrine (NE) levels were higher than normal, while all other pre-treatment hormone levels were within normal range. Low forced expiratory volume in 1 sec (FEV1) was associated with low basal and stimulated TSH (P < 0.01). Urinary NE excretion correlated positively to nocturnal time spent with SaO2<85% (P<0.05). In similarity with normal controls, positive correlations were found between sex hormone binding globulin and testosterone both before and after LTOT (P<0.01). No significant hormonal changes were noted following an average of 8 months of LTOT for the entire study group. However, in a subgroup (n = 6) with an increase in MSaO2 exceeding 7% points following LTOT, nocturnal excretion of NE and epinephrine were reduced by 30% (P<0.05) and S-free thyroxin by 20% (P<0.05). In conclusion, patients with chronic hypoxaemia secondary to COPD exhibit elevated plasma NE levels but otherwise normal endocrine levels, including a normal hypothalamic-pituitary testicular axis. The severity of airway obstruction is associated with reduced basal and stimulated TSH. The endocrine function is not significantly changed following LTOT except for a subgroup with severe nocturnal hypoxaemia, where elevated nocturnal NE excretion was noted, which was reduced only if whole night oxygenation was normalized during oxygen therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192959     DOI: 10.1053/rmed.2000.0953

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  Bidirectional ventricular tachycardia in a patient with exacerbation of chronic obstructive pulmonary disease.

Authors:  Oliver Adam; Christian Ukena; Michael Böhm; Hans-Ruprecht Neuberger
Journal:  Clin Res Cardiol       Date:  2012-05-03       Impact factor: 5.460

Review 2.  Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management.

Authors:  Rohit Budhiraja; Tauseef A Siddiqi; Stuart F Quan
Journal:  J Clin Sleep Med       Date:  2015-03-15       Impact factor: 4.062

3.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.

Authors:  Koen Brusselmans; Veerle Compernolle; Marc Tjwa; Michael S Wiesener; Patrick H Maxwell; Désiré Collen; Peter Carmeliet
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  Chemosensitivity, Cardiovascular Risk, and the Ventilatory Response to Exercise in COPD.

Authors:  Michael K Stickland; Desi P Fuhr; Heather Edgell; Brad W Byers; Mohit Bhutani; Eric Y L Wong; Craig D Steinback
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

5.  Instability of nocturnal parasympathetic nerve function in patients with chronic lung disease with or without nocturnal desaturation.

Authors:  Keisaku Fujimoto; Haruna Yamazaki; Akikazu Uematsu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-09-11

6.  Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Samuel L Krachman; Maria Elena Vega; Daohai Yu; Joseph Demidovich; Harsh Patel; Frederic Jaffe; Xavier Soler; Tahseen Shariff; Gilbert E D'Alonzo; Wissam Chatila; Sheila Weaver; Yasmin Daraz; Sydney Cohen; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-04-27

Review 7.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.

Authors:  Aibek E Mirrakhimov
Journal:  Cardiovasc Diabetol       Date:  2012-10-27       Impact factor: 9.951

Review 8.  Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.

Authors:  Cédric Delporte; Pierre Van Antwerpen; Luc Vanhamme; Thierry Roumeguère; Karim Zouaoui Boudjeltia
Journal:  Mediators Inflamm       Date:  2013-07-24       Impact factor: 4.711

9.  Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis.

Authors:  Evan Atlantis; Paul Fahey; Belinda Cochrane; Gary Wittert; Sheree Smith
Journal:  BMJ Open       Date:  2013-08-13       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.